Impact of CHEK2 germline variants on haematological malignancy risk and outcomes of allogeneic HSCT

: Lahtinen, Atte K.; Karu, Maarja; Koski, Jessica R.; Ritari, Jarmo; Hyvärinen, Kati; Koskela, Satu; Nihtilä, Julia; Partanen, Jukka; Vettenranta, Kim; Koskenvuo, Minna; Niittyvuopio, Riitta; Salmenniemi, Urpu; Itälä‐Remes, Maija; Jahnukainen, Kirsi; Kilpivaara, Outi; Wartiovaara‐Kautto, Ulla

Publisher: Wiley-Blackwell

: 2025

: British Journal of Haematology

: bjh.20196

: 207

: 2

: 636

: 641

: 0007-1048

: 1365-2141

DOI: https://doi.org/10.1111/bjh.20196

: https://doi.org/10.1111/bjh.20196

: https://research.utu.fi/converis/portal/detail/Publication/499131612

Br J Haematol - 2025 - Lahtinen - Impact of CHEK2 germline variants on haematological malignancy risk and outcomes of.pdf

:
This work was supported by the Research Council of Finland #349760, Cancer Foundation Finland, Sigrid Jusélius Foundation, the Finnish Special Governmental Subsidy for Health Sciences, Research, and Training, the Helsinki University Hospital Comprehensive Cancer Research Funding, the Finnish Funding Agency for Technology and Innovation (TEKES), the Väre Foundation for Pediatric Cancer Research, the iCAN Digital Precision Cancer Medicine, Cancer Foundation Finland, Ane and Signe Gyllenberg Foundation, foundation for Pediatric Research, the Swedish Childhood Cancer Foundation (KP2020-0012) and the Birgitta and Carl-Axel Rydbeck's Research Grant for Paediatric Research (2020-00335, 2021-00079 and 2023-00380). We would also like to acknowledge support by the Finnish Medical Foundation, the Finnish Association of Hematology, the Ida Montin Foundation, the Biomedicum Helsinki Foundation and Jalmari and Rauha Ahokas Foundation.